Vertex Pharmaceuticals Incorporated: Hepatitis C, Chronic trials

The registry lists 15 Hepatitis C, Chronic studies with Vertex Pharmaceuticals Incorporated as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 4Phase 2 10Phase 3 2Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis CTerminatedNCT01467492Phase 4Results posted
• Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC GenotypeTerminatedNCT01459913Phase 3Results posted
• A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral ResponseCompletedNCT00758043Phase 3Results posted
• Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis CCompletedNCT00372385Phase 2Results posted
• Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis CCompletedNCT00336479Phase 2Results posted
• A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis CCompletedNCT01842451Phase 2
• A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis CCompletedNCT01726946Phase 2
• VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis CCompletedNCT01581138Phase 2
• A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated CirrhosisCompletedNCT01516918Phase 2
• A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy SubjectsCompletedNCT01511432Phase 1
• Study of VX-985 in Subjects With Chronic Hepatitis CCompletedNCT01144936Phase 1
• A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedNCT01080222Phase 2
• Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C InfectionCompletedNCT00911963Phase 1/2
• A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.CompletedNCT00389298Phase 1/2
• Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis CCompletedNCT00088504Phase 2